Journal of Pediatric Neurology 2018; 16(03): 171-184
DOI: 10.1055/s-0037-1605580
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Neuroimaging in Pediatric Autoimmune Diseases

Giulia Longoni
1   Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
2   Division of Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada
,
Brenda L. Banwell
3   Division of Child Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4   Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
› Author Affiliations
Further Information

Publication History

25 January 2017

15 June 2017

Publication Date:
14 August 2017 (online)

Abstract

Magnetic resonance imaging plays an essential role in the diagnosis and management of pediatric central nervous system (CNS) autoimmune disorders. This article reviews the key clinical and conventional neuroimaging characteristics of the most frequent entities of the demyelinating disease spectrum, with a goal to inform and guide decisions in the clinical practice. We focus on acquired demyelinating syndromes and their differential diagnoses including mimics such as systemic inflammatory disorders with secondary CNS involvement. In the vast majority of disorders, no specific biomarker of disease is known and the final diagnosis is based on recognizable syndromic characteristics. Therefore, familiarity with the related neuroimaging patterns can improve a timely diagnosis of pediatric autoimmune diseases and prompt targeted therapeutic approach.

 
  • References

  • 1 Krupp LB, Tardieu M, Amato MP. , et al; International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013; 19 (10) 1261-1267
  • 2 Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 2002; 59 (08) 1224-1231
  • 3 Mikaeloff Y, Caridade G, Husson B, Suissa S, Tardieu M. ; Neuropediatric KIDSEP Study Group of the French Neuropediatric Society. Acute disseminated encephalomyelitis cohort study: prognostic factors for relapse. Eur J Paediatr Neurol 2007; 11 (02) 90-95
  • 4 Idrissova ZhR, Boldyreva MN, Dekonenko EP. , et al. Acute disseminated encephalomyelitis in children: clinical features and HLA-DR linkage. Eur J Neurol 2003; 10 (05) 537-546
  • 5 Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123 (Pt 12): 2407-2422
  • 6 Banwell B, Bar-Or A, Arnold DL. , et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011; 10 (05) 436-445
  • 7 McKeon A, Lennon VA, Lotze T. , et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008; 71 (02) 93-100
  • 8 Brilot F, Dale RC, Selter RC. , et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66 (06) 833-842
  • 9 Baumann M, Sahin K, Lechner C. , et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86 (03) 265-272
  • 10 Lalive PH, Häusler MG, Maurey H. , et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011; 17 (03) 297-302
  • 11 Di Pauli F, Mader S, Rostasy K. , et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol 2011; 138 (03) 247-254
  • 12 Rostásy K, Mader S, Hennes EM. , et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler 2013; 19 (08) 1052-1059
  • 13 Dale RC, Tantsis EM, Merheb V. , et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014; 1 (01) e12
  • 14 Hacohen Y, Absoud M, Deiva K. , et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015; 2 (02) e81
  • 15 Fernandez-Carbonell C, Vargas-Lowy D, Musallam A. , et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016; 22 (02) 174-184
  • 16 Pröbstel AK, Dornmair K, Bittner R. , et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77 (06) 580-588
  • 17 Baumann M, Hennes EM, Schanda K. , et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016; 22 (14) 1821-1829
  • 18 Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LM. Italian Society of Paediatric Neurology Study Group on childhood multiple S. multiple sclerosis in children under 10 years of age. Neurol Sci 2004; 25 (04) 326-335
  • 19 Banwell B, Krupp L, Kennedy J. , et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007; 6 (09) 773-781
  • 20 Alper G, Heyman R, Wang L. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol 2009; 51 (06) 480-486
  • 21 Leake JA, Albani S, Kao AS. , et al. Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23 (08) 756-764
  • 22 Dale RC, Brilot F, Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2009; 22 (03) 233-240
  • 23 Anlar B, Basaran C, Kose G. , et al. Acute disseminated encephalomyelitis in children: outcome and prognosis. Neuropediatrics 2003; 34 (04) 194-199
  • 24 Callen DJA, Shroff MM, Branson HM. , et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology 2009; 72 (11) 961-967
  • 25 Polman CH, Reingold SC, Banwell B. , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (02) 292-302
  • 26 Verhey LH, Branson HM, Shroff MM. , et al; Canadian Pediatric Demyelinating Disease Network. MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 2011; 10 (12) 1065-1073
  • 27 Absoud M, Lim MJ, Chong WK. , et al; UK and Ireland Childhood CNS Inflammatory Demyelination Working Group. Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features. Mult Scler 2013; 19 (01) 76-86
  • 28 Marques IB, Matias F, Silva ED, Cunha L, Sousa L. Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 2014; 21 (04) 583-586
  • 29 Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology 2006; 67 (02) 258-262
  • 30 Deiva K, Absoud M, Hemingway C. , et al; United Kingdom Childhood Inflammatory Demyelination (UK-CID) Study and French Kidbiosep Study. Acute idiopathic transverse myelitis in children: early predictors of relapse and disability. Neurology 2015; 84 (04) 341-349
  • 31 Alper G, Petropoulou KA, Fitz CR, Kim Y. Idiopathic acute transverse myelitis in children: an analysis and discussion of MRI findings. Mult Scler 2011; 17 (01) 74-80
  • 32 Thomas T, Branson HM, Verhey LH. , et al. The demographic, clinical, and magnetic resonance imaging (MRI) features of transverse myelitis in children. J Child Neurol 2012; 27 (01) 11-21
  • 33 Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007; 68 (18) 1474-1480
  • 34 Absoud M, Greenberg BM, Lim M, Lotze T, Thomas T, Deiva K. Pediatric transverse myelitis. Neurology 2016; 87 (09) (Suppl. 02) S46-S52
  • 35 Makhani N, Morris SK, Page AV. , et al. A twist on Lyme: the challenge of diagnosing European Lyme neuroborreliosis. J Clin Microbiol 2011; 49 (01) 455-457
  • 36 Messacar K, Schreiner TL, Maloney JA. , et al. A cluster of acute flaccid paralysis and cranial nerve dysfunction temporally associated with an outbreak of enterovirus D68 in children in Colorado, USA. Lancet 2015; 385 (9978): 1662-1671
  • 37 Maloney JA, Mirsky DM, Messacar K, Dominguez SR, Schreiner T, Stence NV. MRI findings in children with acute flaccid paralysis and cranial nerve dysfunction occurring during the 2014 enterovirus D68 outbreak. AJNR Am J Neuroradiol 2015; 36 (02) 245-250
  • 38 Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 2009; 15 (05) 627-631
  • 39 Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. ; University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology 2002; 59 (07) 1006-1010
  • 40 Ghezzi A, Deplano V, Faroni J. , et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997; 3 (01) 43-46
  • 41 Sindern E, Haas J, Stark E, Wurster U. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand 1992; 86 (03) 280-284
  • 42 Banwell B, Kennedy J, Sadovnick D. , et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009; 72 (03) 232-239
  • 43 Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009; 66 (01) 54-59
  • 44 Yeh EA, Weinstock-Guttman B, Ramanathan M. , et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009; 132 (Pt 12): 3392-3400
  • 45 Ghassemi R, Narayanan S, Banwell B, Sled JG, Shroff M, Arnold DL. ; Canadian Pediatric Demyelinating Disease Network. Quantitative determination of regional lesion volume and distribution in children and adults with relapsing-remitting multiple sclerosis. PLoS One 2014; 9 (02) e85741
  • 46 Waubant E, Chabas D, Okuda DT. , et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009; 66 (08) 967-971
  • 47 Kerbrat A, Aubert-Broche B, Fonov V. , et al. Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS. Neurology 2012; 78 (03) 194-201
  • 48 Aubert-Broche B, Fonov V, Ghassemi R. , et al. Regional brain atrophy in children with multiple sclerosis. Neuroimage 2011; 58 (02) 409-415
  • 49 Mesaros S, Rocca MA, Absinta M. , et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008; 70 (13 Pt 2): 1107-1112
  • 50 Sadaka Y, Verhey LH, Shroff MM. , et al; Canadian Pediatric Demyelinating Disease Network. 2010 McDonald criteria for diagnosing pediatric multiple sclerosis. Ann Neurol 2012; 72 (02) 211-223
  • 51 Sedani S, Lim MJ, Hemingway C, Wassmer E, Absoud M. Paediatric multiple sclerosis: examining utility of the McDonald 2010 criteria. Mult Scler 2012; 18 (05) 679-682
  • 52 O'Connor KC, Lopez-Amaya C, Gagne D. , et al. Anti-myelin antibodies modulate clinical expression of childhood multiple sclerosis. J Neuroimmunol 2010; 223 (1-2): 92-99
  • 53 Banwell B, Shroff M, Ness JM, Jeffery D, Schwid S, Weinstock-Guttman B. ; International Pediatric MS Study Group. MRI features of pediatric multiple sclerosis. Neurology 2007; 68 (16) (Suppl. 02) S46-S53
  • 54 Chabas D, Castillo-Trivino T, Mowry EM, Strober JB, Glenn OA, Waubant E. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?. Neurology 2008; 71 (14) 1090-1093
  • 55 Mikaeloff Y, Adamsbaum C, Husson B. , et al; KIDMUS Study Group on Radiology. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004; 127 (Pt 9): 1942-1947
  • 56 Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007; 6 (10) 887-902
  • 57 Lucchinetti CF, Popescu BF, Bunyan RF. , et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365 (23) 2188-2197
  • 58 Calabrese M, Gallo P. Magnetic resonance evidence of cortical onset of multiple sclerosis. Mult Scler 2009; 15 (08) 933-941
  • 59 Calabrese M, Seppi D, Romualdi C. , et al. Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population. Am J Neuroradiol 2012; 33 (08) 1507-1511
  • 60 Absinta M, Rocca MA, Moiola L. , et al. Cortical lesions in children with multiple sclerosis. Neurology 2011; 76 (10) 910-913
  • 61 Absinta M, Sati P, Reich DS. Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol 2016; 12 (06) 358-368
  • 62 Sati P, Oh J, Constable RT. , et al; NAIMS Cooperative. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol 2016; 12 (12) 714-722
  • 63 Filippi M, Rocca MA, Ciccarelli O. , et al; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016; 15 (03) 292-303
  • 64 Tintore M, Otero-Romero S, Río J. , et al. Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology 2016; 87 (13) 1368-1374
  • 65 Chitnis T, Tenembaum S, Banwell B. , et al; International Pediatric Multiple Sclerosis Study Group. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012; 18 (01) 116-127
  • 66 Banwell B, Arnold DL, Tillema JM. , et al. MRI in the evaluation of pediatric multiple sclerosis. Neurology 2016; 87 (09) (Suppl. 02) S88-S96
  • 67 Kanda T, Oba H, Toyoda K, Kitajima K, Furui S. Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016; 34 (01) 3-9
  • 68 Hummel HM, Brück W, Dreha-Kulaczewski S, Gärtner J, Wuerfel J. Pediatric onset multiple sclerosis: McDonald criteria 2010 and the contribution of spinal cord MRI. Mult Scler 2013; 19 (10) 1330-1335
  • 69 Wingerchuk DM, Banwell B, Bennett JL. , et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (02) 177-189
  • 70 Lechner C, Baumann M, Hennes EM. , et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016; 87 (08) 897-905
  • 71 Chitnis T, Ness J, Krupp L. , et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016; 86 (03) 245-252
  • 72 Kitley J, Waters P, Woodhall M. , et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71 (03) 276-283
  • 73 Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci 2016; 1366 (01) 20-39
  • 74 Tenembaum S, Chitnis T, Nakashima I. , et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 2016; 87 (09) (Suppl. 02) S59-S66
  • 75 Mader S, Gredler V, Schanda K. , et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184
  • 76 Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun 2014; 2: 35
  • 77 Spadaro M, Gerdes LA, Mayer MC. , et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol 2015; 2 (03) 295-301
  • 78 Di Pauli F, Höftberger R, Reindl M. , et al. Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm 2015; 2 (06) e175
  • 79 Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?. Neurol Neuroimmunol Neuroinflamm 2015; 2 (01) e62
  • 80 Banwell B, Tenembaum S, Lennon VA. , et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008; 70 (05) 344-352
  • 81 Tenembaum S, Chitnis T, Ness J, Hahn JS. ; International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007; 68 (16) (Suppl. 02) S23-S36
  • 82 Verhey LH, Branson HM, Makhija M, Shroff M, Banwell B. Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology 2010; 52 (12) 1153-1162
  • 83 Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63 (03) 390-396
  • 84 Collongues N, Marignier R, Zéphir H. , et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 2010; 75 (12) 1084-1088
  • 85 Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008; 122 (05) e1039-e1047
  • 86 Absoud M, Lim MJ, Appleton R. , et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features. J Neurol Neurosurg Psychiatry 2015; 86 (04) 470-472
  • 87 Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012; 32 (03) 216-220
  • 88 Kim HJ, Paul F, Lana-Peixoto MA. , et al; Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015; 84 (11) 1165-1173
  • 89 Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013; 33 (02) 123-127
  • 90 Graves J, Kraus V, Soares BP, Hess CP, Waubant E. Longitudinally extensive optic neuritis in pediatric patients. J Child Neurol 2015; 30 (01) 120-123
  • 91 Nakamura M, Miyazawa I, Fujihara K. , et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study. J Neurol 2008; 255 (02) 163-170
  • 92 Cassinotto C, Deramond H, Olindo S, Aveillan M, Smadja D, Cabre P. MRI of the spinal cord in neuromyelitis optica and recurrent longitudinal extensive myelitis. J Neuroradiol 2009; 36 (04) 199-205
  • 93 Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10) 1485-1489
  • 94 Verhey LH, Banwell BL. Inflammatory, vascular, and infectious myelopathies in children. Handb Clin Neurol 2013; 112: 999-1017
  • 95 Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. “Cloud-like enhancement” is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009; 66 (03) 425-428
  • 96 Jarius S, Ruprecht K, Kleiter I. , et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13 (01) 279
  • 97 Jarius S, Ruprecht K, Kleiter I. , et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13 (01) 280
  • 98 Jarius S, Kleiter I, Ruprecht K. , et al; in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation 2016; 13 (01) 281
  • 99 Rostasy K, Mader S, Schanda K. , et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012; 69 (06) 752-756
  • 100 Sato DK, Callegaro D, Lana-Peixoto MA. , et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82 (06) 474-481
  • 101 Jarius S, Ruprecht K, Wildemann B. , et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012; 9: 14
  • 102 Sato DK, Nakashima I, Takahashi T. , et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology 2013; 80 (24) 2210-2216
  • 103 Kitley J, Leite MI, Küker W. , et al. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 2013; 70 (11) 1375-1381
  • 104 Thulasirajah S, Pohl D, Davila-Acosta J, Venkateswaran S. Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination: clinical course, neuroimaging findings, and response to therapy. Neuropediatrics 2016; 47 (04) 245-252
  • 105 Dalmau J, Gleichman AJ, Hughes EG. , et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008; 7 (12) 1091-1098
  • 106 Granerod J, Ambrose HE, Davies NW. , et al; UK Health Protection Agency (HPA) Aetiology of Encephalitis Study Group. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis 2010; 10 (12) 835-844
  • 107 Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis 2012; 54 (07) 899-904
  • 108 Titulaer MJ, McCracken L, Gabilondo I. , et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (02) 157-165
  • 109 Florance NR, Davis RL, Lam C. , et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009; 66 (01) 11-18
  • 110 Irani SR, Bera K, Waters P. , et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133 (Pt 6): 1655-1667
  • 111 Wright S, Hacohen Y, Jacobson L. , et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children. Arch Dis Child 2015; 100 (06) 521-526
  • 112 Hacohen Y, Absoud M, Hemingway C. , et al. NMDA receptor antibodies associated with distinct white matter syndromes. Neurol Neuroimmunol Neuroinflamm 2014; 1 (01) e2
  • 113 Titulaer MJ, Höftberger R, Iizuka T. , et al. Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75 (03) 411-428
  • 114 Benseler S, Pohl D. Childhood central nervous system vasculitis. Handb Clin Neurol 2013; 112: 1065-1078
  • 115 Elbers J, Halliday W, Hawkins C, Hutchinson C, Benseler SM. Brain biopsy in children with primary small-vessel central nervous system vasculitis. Ann Neurol 2010; 68 (05) 602-610
  • 116 Hajj-Ali RA, Calabrese LH. Primary angiitis of the central nervous system. Autoimmun Rev 2013; 12 (04) 463-466
  • 117 Ozen S, Pistorio A, Iusan SM. , et al; Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis 2010; 69 (05) 798-806
  • 118 Bérubé MD, Blais N, Lanthier S. Neurologic manifestations of Henoch-Schönlein purpura. Handb Clin Neurol 2014; 120: 1101-1111
  • 119 Abend NS, Licht DJ, Spencer CH. Lupus anticoagulant and thrombosis following Henoch-Schonlein purpura. Pediatr Neurol 2007; 36 (05) 345-347
  • 120 Belman AL, Leicher CR, Moshé SL, Mezey AP. Neurologic manifestations of Schoenlein-Henoch purpura: report of three cases and review of the literature. Pediatrics 1985; 75 (04) 687-692
  • 121 De Luna G, Terrier B, Kaminsky P. , et al; French Vasculitis Study Group (FVSG). Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. Rheumatology (Oxford) 2015; 54 (03) 424-432
  • 122 Iudici M, Quartier P, Terrier B, Mouthon L, Guillevin L, Puéchal X. Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet J Rare Dis 2016; 11 (01) 141
  • 123 Sun L, Wang H, Jiang X. , et al. Clinical and pathological features of microscopic polyangiitis in 20 children. J Rheumatol 2014; 41 (08) 1712-1719
  • 124 Gendelman S, Zeft A, Spalding SJ. Childhood-onset eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): a contemporary single-center cohort. J Rheumatol 2013; 40 (06) 929-935
  • 125 Lu T, Bao J, Lin D, Chen H, Qiu W, Lu Z. Pediatric granulomatosis with polyangiitis exhibiting prominent central nervous system symptoms. Childs Nerv Syst 2016; 32 (08) 1517-1521
  • 126 Akman-Demir G, Serdaroglu P, Tasçi B. ; The Neuro-Behçet Study Group. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999; 122 (Pt 11): 2171-2182
  • 127 Siva A, Kantarci OH, Saip S. , et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001; 248 (02) 95-103
  • 128 Kidd D. Neurological complications of Behçet's syndrome. Curr Neurol Neurosci Rep 2012; 12 (06) 675-679
  • 129 Cakar N, Başaran O, Uncu N. , et al. Clinical characteristics of paediatric neuro-Behçet's disease: a single tertiary centre experience. Clin Exp Rheumatol 2014; 32 (04) (Suppl. 84) S165-S170
  • 130 Hirohata S, Kikuchi H, Sawada T. , et al. Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol 2012; 22 (03) 405-413
  • 131 Borhani Haghighi A, Sarhadi S, Farahangiz S. MRI findings of neuro-Behcet's disease. Clin Rheumatol 2011; 30 (06) 765-770
  • 132 Ishida S, Shiima C, Edagawa G, Sakane S, Furukawa K. Serial MRI findings in a relapsing-remitting form of neuro-Behçet's disease: a case report. Clin Imaging 2004; 28 (06) 399-403
  • 133 Lee SH, Yoon PH, Park SJ, Kim DI. MRI findings in neuro-Behçet's disease. Clin Radiol 2001; 56 (06) 485-494
  • 134 Saltik S, Saip S, Kocer N, Siva A, Yalçinkaya C. MRI findings in pediatric neuro-Behçet's disease. Neuropediatrics 2004; 35 (03) 190-193
  • 135 Yildiz S, Boyaci N, Sen Dokumaci D, Boyaci A. Different diffusion-weighted MRI findings in brainstem neuro-Behçet's disease. BMJ Case Rep 2013; 2013: bcr201300738
  • 136 Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364 (9433): 533-544
  • 137 Terai M, Honda T, Yasukawa K, Higashi K, Hamada H, Kohno Y. Prognostic impact of vascular leakage in acute Kawasaki disease. Circulation 2003; 108 (03) 325-330
  • 138 Alves NR, Magalhães CM, Almeida RdeF, Santos RC, Gandolfi L, Pratesi R. Prospective study of Kawasaki disease complications: review of 115 cases. Rev Assoc Med Bras (1992) 2011; 57 (03) 295-300
  • 139 Terasawa K, Ichinose E, Matsuishi T, Kato H. Neurological complications in Kawasaki disease. Brain Dev 1983; 5 (04) 371-374
  • 140 Ka A, Britton P, Troedson C. , et al. Mild encephalopathy with reversible splenial lesion: an important differential of encephalitis. Eur J Paediatr Neurol 2015; 19 (03) 377-382
  • 141 Muneuchi J, Kusuhara K, Kanaya Y. , et al. Magnetic resonance studies of brain lesions in patients with Kawasaki disease. Brain Dev 2006; 28 (01) 30-33
  • 142 Gitiaux C, Kossorotoff M, Bergounioux J. , et al. Cerebral vasculitis in severe Kawasaki disease: early detection by magnetic resonance imaging and good outcome after intensive treatment. Dev Med Child Neurol 2012; 54 (12) 1160-1163
  • 143 Sabatier I, Chabrier S, Brun A. , et al. Stroke by carotid artery complete occlusion in Kawasaki disease: case report and review of literature. Pediatr Neurol 2013; 49 (06) 469-473
  • 144 Jennette JC, Falk RJ, Bacon PA. , et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65 (01) 1-11
  • 145 Ozen S, Anton J, Arisoy N. , et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 2004; 145 (04) 517-522
  • 146 Guillevin L, Mahr A, Callard P. , et al; French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84 (05) 313-322
  • 147 Gulati S, Patel NP, Swierczynski SL. Vasculitides associated with haematological malignancies: a case-based review. BMJ Case Rep 2012; 2012: bcr2012007123
  • 148 Lai FY, Gröschel MI, van den Hende L, Diercks GF, Rutgers A, van der Werf TS. Prolonged pyrexia and subtle skin lesions: polyarteritis nodosa. Lancet 2016; 387 (10022): 1025-1026
  • 149 Henegar C, Pagnoux C, Puéchal X. , et al; French Vasculitis Study Group. A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum 2008; 58 (05) 1528-1538
  • 150 Falcini F, La Torre F, Vittadello F. , et al. Clinical overview and outcome in a cohort of children with polyarteritis nodosa. Clin Exp Rheumatol 2014; 32 (03) (Suppl. 82) S134-S137
  • 151 Ettlinger RE, Nelson AM, Burke EC, Lie JT. Polyarteritis nodosa in childhood a clinical pathologic study. Arthritis Rheum 1979; 22 (08) 820-825
  • 152 Eleftheriou D, Dillon MJ, Tullus K. , et al. Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years. Arthritis Rheum 2013; 65 (09) 2476-2485
  • 153 Ueno K, Matsushima A, Hineno A. , et al. Polyarteritis nodosa with central nervous system involvement mimicking relapsing-remitting multiple sclerosis. Mod Rheumatol 2014; 24 (03) 525-528
  • 154 Dörr J, Krautwald S, Wildemann B. , et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol 2013; 9 (06) 307-316
  • 155 Jarius S, Kleffner I, Dörr JM. , et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation 2014; 11: 46
  • 156 Mateen FJ, Zubkov AY, Muralidharan R. , et al. Susac syndrome: clinical characteristics and treatment in 29 new cases. Eur J Neurol 2012; 19 (06) 800-811
  • 157 Wuerfel J, Sinnecker T, Ringelstein EB. , et al. Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult Scler 2012; 18 (11) 1592-1599
  • 158 Sibbitt Jr WL, Brandt JR, Johnson CR. , et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002; 29 (07) 1536-1542
  • 159 Harel L, Sandborg C, Lee T, von Scheven E. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol 2006; 33 (09) 1873-1877
  • 160 Yu HH, Lee JH, Wang LC, Yang YH, Chiang BL. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. Lupus 2006; 15 (10) 651-657
  • 161 Hanly JG, Urowitz MB, Su L. , et al; Systemic Lupus International Collaborating Clinics (SLICC). Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010; 69 (03) 529-535
  • 162 Al-Obaidi M, Saunders D, Brown S. , et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2016; 35 (10) 2449-2456
  • 163 Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005; 31 (02) 273-298 , vi
  • 164 Hanly JG, Urowitz MB, Su L. , et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70 (10) 1726-1732
  • 165 Govoni M, Bortoluzzi A, Padovan M. , et al. The diagnosis and clinical management of the neuropsychiatric manifestations of lupus. J Autoimmun 2016; 74: 41-72
  • 166 Luyendijk J, Steens SC, Ouwendijk WJ. , et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2011; 63 (03) 722-732
  • 167 Sarbu N, Alobeidi F, Toledano P. , et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev 2015; 14 (02) 153-159
  • 168 Csépány T, Bereczki D, Kollár J, Sikula J, Kiss E, Csiba L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 2003; 250 (11) 1348-1354
  • 169 Toledano P, Sarbu N, Espinosa G, Bargalló N, Cervera R. Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features. Autoimmun Rev 2013; 12 (12) 1166-1170
  • 170 Verma R, Nagar KK, Mehta M. Recurrent myelopathy and optic neuritis associated with systemic lupus erythematosus. Neurol India 2016; 64 (04) 798-800
  • 171 Costallat BL, Ferreira DM, Costallat LT, Appenzeller S. Myelopathy in systemic lupus erythematosus: clinical, laboratory, radiological and progression findings in a cohort of 1,193 patients. Rev Bras Reumatol Engl Ed 2016; 56 (03) 240-251
  • 172 Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000; 59 (02) 120-124
  • 173 Quintanilla-González L, Atisha-Fregoso Y, Llorente L, Fragoso-Loyo H. Myelitis in systemic lupus erythematosus: clinical characteristics and effect in accrual damage. A single-center experience. Lupus 2017; 26 (03) 248-254
  • 174 Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet 2014; 383 (9923): 1155-1167
  • 175 Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. Am J Neuroradiol 2009; 30 (05) 953-961
  • 176 Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci 2011; 1: 15
  • 177 Baumann RJ, Robertson Jr WC. Neurosarcoid presents differently in children than in adults. Pediatrics 2003; 112 (6 Pt 1): e480-e486
  • 178 Spencer TS, Campellone JV, Maldonado I, Huang N, Usmani Q, Reginato AJ. Clinical and magnetic resonance imaging manifestations of neurosarcoidosis. Semin Arthritis Rheum 2005; 34 (04) 649-661
  • 179 Bathla G, Singh AK, Policeni B, Agarwal A, Case B. Imaging of neurosarcoidosis: common, uncommon, and rare. Clin Radiol 2016; 71 (01) 96-106
  • 180 Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3 (07) 397-407
  • 181 Pittock SJ, Debruyne J, Krecke KN. , et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2010; 133 (09) 2626-2634
  • 182 Cohen-Aubart F, Galanaud D, Grabli D. , et al. Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 2010; 89 (02) 133-140
  • 183 Nozaki K, Scott TF, Sohn M, Judson MA. Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist 2012; 18 (06) 373-377
  • 184 Flanagan EP, Kaufmann TJ, Krecke KN. , et al. Discriminating long myelitis of neuromyelitis optica from sarcoidosis. Ann Neurol 2016; 79 (03) 437-447
  • 185 Cornec D, Saraux A, Cochener B. , et al. Level of agreement between 2002 American-European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren's syndrome and reasons for discrepancies. Arthritis Res Ther 2014; 16 (02) R74
  • 186 Barone F, Colafrancesco S. Sjögren's syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol 2016; 34 (04) (Suppl. 98) 58-62
  • 187 Carvajal Alegria G, Guellec D, Mariette X. , et al. Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort. RMD Open 2016; 2 (01) e000179
  • 188 Matsui Y, Takenouchi T, Narabayashi A, Ohara K, Nakahara T, Takahashi T. Childhood Sjögren syndrome presenting as acute brainstem encephalitis. Brain Dev 2016; 38 (01) 158-162
  • 189 Rossi R, Valeria Saddi M. Subacute aseptic meningitis as neurological manifestation of primary Sjögren's syndrome. Clin Neurol Neurosurg 2006; 108 (07) 688-691
  • 190 Rovira Á, Auger C, Rovira A. Other noninfectious inflammatory disorders. Handb Clin Neurol 2016; 135: 425-446
  • 191 Thongpooswan S, Chapagain B, Bandagi S. A rare case of neuromyelitis optica spectrum disorder in patient with Sjogren's syndrome. Case Rep Rheumatol 2014; 2014: 158165
  • 192 Park JH, Hwang J, Min JH, Kim BJ, Kang ES, Lee KH. Presence of anti-Ro/SSA antibody may be associated with anti-aquaporin-4 antibody positivity in neuromyelitis optica spectrum disorder. J Neurol Sci 2015; 348 (1-2): 132-135
  • 193 Emile JF, Abla O, Fraitag S. , et al; Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127 (22) 2672-2681
  • 194 Deiva K, Mahlaoui N, Beaudonnet F. , et al. CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology 2012; 78 (15) 1150-1156
  • 195 Marc T, Kevin R. Neurological expression of genetic immunodeficiencies and of opportunistic infections. Handb Clin Neurol 2013; 112: 1219-1227
  • 196 Henter JI, Horne A, Aricó M. , et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48 (02) 124-131
  • 197 Bien CG, Granata T, Antozzi C. , et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005; 128 (Pt 3): 454-471
  • 198 Varadkar S, Bien CG, Kruse CA. , et al. Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol 2014; 13 (02) 195-205
  • 199 Avberšek A, Miserocchi A, McEvoy AW. , et al. Multiphasic presentation of Rasmussen's encephalitis. Epileptic Disord 2015; 17 (03) 315-320
  • 200 Chiapparini L, Granata T, Farina L. , et al. Diagnostic imaging in 13 cases of Rasmussen's encephalitis: can early MRI suggest the diagnosis?. Neuroradiology 2003; 45 (03) 171-183
  • 201 Granata T, Gobbi G, Spreafico R. , et al. Rasmussen's encephalitis: early characteristics allow diagnosis. Neurology 2003; 60 (03) 422-425